These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 18042482)

  • 1. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes.
    Orzeck EA; Shi N; Blumentals WA
    Clin Ther; 2007 Oct; 29(10):2246-55. PubMed ID: 18042482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: results from a retrospective population-based study.
    Blumentals WA; Schulman KL
    Curr Med Res Opin; 2007 Dec; 23(12):2961-70. PubMed ID: 17939881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions.
    Piedra PA; Schulman KL; Blumentals WA
    Pediatrics; 2009 Jul; 124(1):170-8. PubMed ID: 19564297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study.
    Nordstrom BL; Oh K; Sacks ST; L'Italien GJ
    Antivir Ther; 2004 Apr; 9(2):187-95. PubMed ID: 15134180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.
    Kaiser L; Wat C; Mills T; Mahoney P; Ward P; Hayden F
    Arch Intern Med; 2003 Jul; 163(14):1667-72. PubMed ID: 12885681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005.
    Peters PH; Moscona A; Schulman KL; Barr CE
    Medscape J Med; 2008 Jun; 10(6):131. PubMed ID: 18679536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with early hospital discharge of adult influenza patients.
    Lee N; Chan PK; Choi KW; Lui G; Wong B; Cockram CS; Hui DS; Lai R; Tang JW; Sung JJ
    Antivir Ther; 2007; 12(4):501-8. PubMed ID: 17668558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oseltamivir and influenza-related complications, hospitalization and healthcare expenditure in healthy adults and children.
    Gums JG; Pelletier EM; Blumentals WA
    Expert Opin Pharmacother; 2008 Feb; 9(2):151-61. PubMed ID: 18201141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment.
    Smith JR; Sacks S
    Int J Clin Pract; 2009 Apr; 63(4):596-605. PubMed ID: 19335705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of influenza infection managed with oseltamivir in lung transplant recipients.
    Ison MG; Sharma A; Shepard JA; Wain JC; Ginns LC
    J Heart Lung Transplant; 2008 Mar; 27(3):282-8. PubMed ID: 18342750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health outcomes among patients receiving oseltamivir.
    Enger C; Nordstrom BL; Thakrar B; Sacks S; Rothman KJ
    Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):227-37. PubMed ID: 15255089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population].
    Lin JT; Yu XZ; Cui DJ; Chen XY; Zhu JH; Wang YZ; Wu XD; Gao H; Huo ZL; Zhu SH; Hu SL; Wang AX
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jul; 27(7):455-9. PubMed ID: 15312558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost associated with the treatment of influenza in a managed care setting.
    Cox F; Khan ZM; Schweinle JE; Okamoto L; McLaughlin T
    MedGenMed; 2000 Oct; 2(4):E34. PubMed ID: 11104480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases.
    Casscells SW; Granger E; Kress AM; Linton A; Madjid M; Cottrell L
    Circ Cardiovasc Qual Outcomes; 2009 Mar; 2(2):108-15. PubMed ID: 20031822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents.
    Whitley RJ; Monto AS
    J Infect Dis; 2006 Nov; 194 Suppl 2():S133-8. PubMed ID: 17163386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients hospitalized with 2009 pandemic influenza A (H1N1) - New York City, May 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Jan; 58(51):1436-40. PubMed ID: 20057350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis.
    Siedler K; Skopnik H
    Pediatr Infect Dis J; 2010 Jun; 29(6):495-8. PubMed ID: 20035245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes.
    Postma MJ; Beardsworth P; Wilschut JC
    J Med Econ; 2008; 11(4):743-68. PubMed ID: 19450079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.
    Adisasmito W; Chan PK; Lee N; Oner AF; Gasimov V; Aghayev F; Zaman M; Bamgboye E; Dogan N; Coker R; Starzyk K; Dreyer NA; Toovey S
    J Infect Dis; 2010 Oct; 202(8):1154-60. PubMed ID: 20831384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.